每经头条（nbdtoutiao）——超10万人挤爆服务器，围观8家房企抢"马场"：9小时竞价243轮，236亿元 成交！广州楼面价新地王诞生：8.5万元/㎡ （记者 曾健辉） 每经AI快讯，智飞生物2月26日晚间发布公告称，重庆智飞生物制品股份有限公司（以下简称"公司"） 于近日收到全资子公司安徽智飞龙科马生物制药有限公司（以下简称"智飞龙科马"）报告，由智飞龙科 马自主研发的HK.3-JN.1新型冠状病毒mRNA疫苗获得国家药品监督管理局药物临床试验批准通知书 （通知书编号：2026LP00481），同意本品开展预防新型冠状病毒感染所致疾病的临床试验。 ...

智飞生物(300122.SZ)公告，公司近日收到全资子公司安徽智飞龙科马生物制药有限公司报告，由智飞 龙科马自主研发的HK.3-JN.1新型冠状病毒mRNA疫苗获得国家药品监督管理局药物临床试验批准通知 书，同意本品开展预防新型冠状病毒感染所致疾病的临床试验。 ...

Core Viewpoint - Moderna is facing significant financial pressure due to declining vaccine sales, leading to a decision to cut approximately 10% of its workforce, which has resulted in a sharp decline in its stock price [1][3][6]. Financial Performance - Moderna's stock price has dropped over 90% from its peak, with its market capitalization plummeting from nearly $200 billion (approximately 1.44 trillion RMB) to under $10.5 billion (approximately 75.7 billion RMB) [6]. - The company reported a more than 75% decline in stock price over the past year, indicating a deteriorating financial situation [6]. Workforce Reduction - The layoffs will affect hundreds of employees globally, with the total number of employees expected to fall below 5,000 by the end of the year [5][6]. - CEO Stephane Bancel emphasized the necessity of restructuring operations to align cost structures with actual business needs while maintaining a focus on research investment [3]. Strategic Challenges - Moderna is facing multiple challenges, including criticism from U.S. health officials that has led to changes in vaccine recommendations, impacting the market for its latest vaccine [7]. - The company has also canceled plans for a new mRNA production facility in Japan due to changes in the global business environment [6]. Revenue Projections - Moderna has significantly lowered its revenue expectations for the year, particularly for its RSV vaccine, which has not gained widespread market attention [8]. - The company has postponed its goal of achieving breakeven profitability by two years, now expecting to reach this milestone by 2028 instead of 2026 [8]. Future Outlook - Despite current challenges, CEO Bancel remains optimistic about Moderna's future, citing three approved products and the potential for up to eight additional products to be approved in the next three years [9]. - The company continues to invest in the development of a new generation of COVID-19 vaccines, with recent FDA approval for a third vaccine targeting new variants [9]. Competitive Landscape - Comparatively, BioNTech, another vaccine manufacturer, has successfully adjusted its strategy post-pandemic, resulting in a stock price increase of nearly 25% over the past year, with a market capitalization exceeding $26 billion, more than double that of Moderna [9].